Kinaset Therapeutics

aid: kinaset-therapeutics
name: Kinaset Therapeutics
description: 'Kinaset Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Medfield, Massachusetts, founded
  in 2020 by Robert Clarke (CEO), Roger Heerman (COO) and Frazer Morgan (CDO) to develop novel inhaled therapeutics for severe
  respiratory disease. Its lead candidate, frevecitinib (KN-002), is a dry-powder inhaled pan-JAK inhibitor — potent and balanced
  across JAK1, JAK2, JAK3 and TYK2 — designed as a non-invasive anti-inflammatory add-on to standard of care for all severe
  asthma patients regardless of the underlying cause of inflammation, and explored in COPD. The company completed a Phase
  1/1b program (NCT05006521), received FDA IND clearance, and in July 2026 dosed the first patient in the Phase 2b PANAIRAMA
  trial (NCT07532265) after closing a $103M oversubscribed Series B in January 2026 led by RA Capital Management and Forge
  Life Science Partners, with EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors,
  Sixty Degree Capital, Atlas Venture, 5AM Ventures and Gimv participating on roughly $143M raised to date. Kinaset is a drug
  developer, not a software company: its product is a clinical pipeline, and it publishes no developer program, no public
  API, no SDKs, no webhooks and no machine-readable API contract. Its entire public surface is a 34-page Squarespace marketing
  and investor-news site whose robots.txt disallows every platform JSON view and blocks the major AI crawlers by user agent.'
url: https://raw.githubusercontent.com/api-evangelist/kinaset-therapeutics/refs/heads/main/apis.yml
image: https://images.squarespace-cdn.com/content/6074890838dd81772d76a539/a1b26a82-6ba5-42b8-a5b7-d9307544c035/Kinaset-share-social.png?content-type=image%2Fpng
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Stage
- Drug Discovery
- Respiratory
- Asthma
- COPD
- Inhaled Therapeutics
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/kinaset-therapeutics-domain-security.yml
- type: Website
  url: https://www.kinasettherapeutics.com/
- type: News
  url: https://www.kinasettherapeutics.com/news
- type: About
  url: https://www.kinasettherapeutics.com/about-us
- type: LinkedIn
  url: https://www.linkedin.com/company/kinaset-tx/
- type: Profile
  name: Nasdaq Private Market secondary-market venue listing
  url: https://www.nasdaqprivatemarket.com/
- type: LLMsTxt
  url: llms/kinaset-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Kinaset Therapeutics is a clinical-stage inhaled-respiratory drug developer whose product is the frevecitinib (KN-002)
    pipeline, not software; its whole public surface is a 34-URL Squarespace marketing and investor-news site with no developer,
    API or docs route, no api/developer/docs subdomain (NXDOMAIN on all three), no GitHub organization and no first-party
    package on any registry, and its robots.txt additionally disallows every Squarespace JSON view and blocks the major AI
    crawlers by user agent.
  evidence:
  - url: https://www.kinasettherapeutics.com/openapi.json
    status: 404
  - url: https://www.kinasettherapeutics.com/swagger.json
    status: 404
  - url: https://www.kinasettherapeutics.com/api-docs
    status: 404
  - url: https://www.kinasettherapeutics.com/graphql
    status: 404
  - url: https://www.kinasettherapeutics.com/_api/mcp
    status: 404
  - url: https://www.kinasettherapeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://www.kinasettherapeutics.com/.well-known/agent.json
    status: 404
  - url: https://www.kinasettherapeutics.com/.well-known/security.txt
    status: 404
  - url: https://www.kinasettherapeutics.com/llms.txt
    status: 404
  - url: https://www.kinasettherapeutics.com/sitemap.xml
    status: 200
  checked: '2026-08-23'